SCHEMBL635860

SCHEMBL635860

Nc1ccn([C@@H]2O[C@H](C(O)=C=O)[C@@H](O)[C@H]2O)c(=O)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
THRB P10828 1/20 0.60
MTOR P42345 1/20 0.60
MDM2 Q00987 1/20 0.60
NCOA1 Q15788 1/20 0.60
NCOA3 Q9Y6Q9 1/20 0.60
NT5E P21589 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.44
ST6GAL1 P15907 1/20 0.43
TSHR P16473 1/20 0.43
GLA P06280 1/20 0.43
P2RY2 P41231 1/20 0.43
PDE3A Q14432 2/20 0.43
PDE4D Q08499 1/20 0.43
SLC29A1 Q99808 1/20 0.43
CACNA1F O60840 1/20 0.41
ALB P02768 1/20 0.41
MAPT P10636 1/20 0.41
CACNA1D Q01668 1/20 0.41
CACNA1S Q13698 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27357267 0.99 LMNA (0.59) LMNATHRBMTORMDM2NCOA1
Water SCHEMBL27602266 0.99 LMNA (0.59) LMNATHRBMTORMDM2NCOA1
SCHEMBL27267987 0.89 LMNA (0.59) LMNATHRBMTORMDM2NCOA1
SCHEMBL3630055 0.89 LMNA (0.59) LMNATHRBMTORMDM2NCOA1
SCHEMBL3266289 0.86 LMNA (0.64) LMNATHRBMTORMDM2NCOA1
SCHEMBL1981224 0.85 LMNA (0.63) LMNATHRBMTORMDM2NCOA1
SCHEMBL5154901 0.84 LMNA (0.62) LMNATHRBMTORMDM2NCOA1
Hydrochloric Acid SCHEMBL6946856 0.84 LMNA (0.62) LMNATHRBMTORMDM2NCOA1
SCHEMBL3404713 0.82 LMNA (0.60) LMNATHRBMTORMDM2NCOA1
SCHEMBL27267985 0.82 LMNA (0.60) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101861320-A Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein HANMI PHARM IND CO LTD 2010-10-13 CN claimed
CN-1053194-C Process for N-acyl-5-fluorocytidine derivatives HOFFMANN LA ROCHE (CH) 2000-06-07 CN claimed
CN-1126726-A Process for N-acyl-5-fluorocytidine derivatives HOFFMANN LA ROCHE (CH) 1996-07-17 CN claimed
CN-102858791-A Process for producing fluorocytidine derivatives SCINOPHARM TAIWAN LTD 2013-01-02 CN disclosed
EP-2419135-A1 COMBINATION THERAPY USING AN ANTI-EGFR AGENT(S) AND IGF-1R SPECIFIC INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-02-22 EP disclosed
WO-2010120592-A1 COMBINATION THERAPY USING AN ANTI-EGFR AGENT(S) AND IGF-1R SPECIFIC INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-10-21 WO disclosed
CN-101861320-A Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein HANMI PHARM IND CO LTD 2010-10-13 CN disclosed
EP-2171447-A1 HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY SCHERING CORPORATION (US) 2010-04-07 EP disclosed
WO-2008156613-A1 HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY SCHERING CORPORATION (US) 2008-12-24 WO disclosed
CN-1053194-C Process for N-acyl-5-fluorocytidine derivatives HOFFMANN LA ROCHE (CH) 2000-06-07 CN disclosed
CN-1035675-C Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives HOFFMANN LA ROCHE (CH) 1997-08-20 CN disclosed
CN-1126726-A Process for N-acyl-5-fluorocytidine derivatives HOFFMANN LA ROCHE (CH) 1996-07-17 CN disclosed
CN-1095070-A Preparation N 4-acyl group-5 '-novel method of deoxidation-5-fluorcytidines HOFFMANN LA ROCHE (CH) 1994-11-16 CN disclosed